SeekIn has entered a strategic collaboration with Oncolnv to globally expand the accessibility of its multiple cancer detection tests.
The agreement was made official at the Inspire2Live Annual Congress in Amsterdam, the Netherlands, held last month.
As of this month, Oncolnv will distribute SeekIn's cancer detection tests, including SeekInCare, SeekInCure, and SeekInClarity, OncoSeek, across 12 countries.
The countries are Bulgaria, Belgium, Costa Rica, Egypt, Kenya, Ghana, the Netherlands, Qatar, Nigeria, Tanzania, Singapore, and the UAE.
The OncoSeek test will use seven protein tumour markers to screen for nine common cancer types.
Oncolnv's other three tests are tailored for early cancer detection, recurrence monitoring, and treatment monitoring, respectively. They use shallow whole genomic sequencing and protein tumour markers.
SeekIn founder and CEO Dr Mao Mao said: “We are thrilled to join forces with Inspire2Live and Oncolnv, two patient-centric organisations committed to revolutionising cancer detection and treatment.
“With their extensive network and dedication to the cause, we can better serve cancer patients globally, providing them with advanced detection technologies and empowering healthcare providers with the tools that they need to fight this devastating disease.”
This partnership paves the way for upcoming research initiatives, fostering possibilities for joint clinical studies and information exchange, as well as collaborative development of advanced cancer detection methodologies.
Furthermore, the collaborative effort intends to enhance patient outcomes and increase survival rates by leveraging the expertise of both organisations.
Inspire2Live founder Peter Kapitein said: “This collaboration aligns perfectly with our organisation's vision of a world where access to quality cancer care is universal. Together, we can make a real difference in the lives of countless patients around the globe.”
SeekIn leverages next-generation sequencing and artificial intelligence and focuses on pan-cancer early detection. It offers solutions for cancer early detection, postoperative recurrence monitoring, and treatment response evaluation.
